Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs

NASDAQ:ISRG

Intuitive Surgical Inc. (ISRG)

374.48
-23.24 (5.84%)
as of Aug 20, 2026, 8:00:00 pm Market Open.
129 watching
0
Investor Insights
star iconAug 20, 2026, 12:00 am

This summary was created by AI, based on 6 opinions in the last 12 months.

Intuitive Surgical Inc. (ISRG-Q) is viewed positively by various experts, particularly due to its focus on robotic surgeries, which are expected to grow significantly in the future. Despite recent challenges in the medical technology sector and a weaker last quarter, many see the stock as an attractive investment for those with a long-term horizon. Experts suggest that while current market conditions present opportunities, there is a cautionary note regarding increasing competition from firms like Medtronic and the potential impact of tariffs on profit margins. The consensus suggests a need for a better entry point, indicating a waiting strategy among investors. Overall, Intuitive Surgical is recognized for its innovative solutions in surgery, yet the outlook is tempered by concerns about price pressure and market competition.

consensus icon
Consensus
Bullish
valuation icon
Valuation
Fair Value
review icon
Similar
ABMD
BUY

JNJ JNJ is trying to respond to the rise of robotic surgery by Intuitive Surgical, which he prefers. This take time and research for JNJ, which means Intuitive will still be ahead of JNJ.

BUY

Allan Tong’s Discover Picks Both Jamie Murray and Bruce Murray (unrelated) see strong long-term growth ahead for the company as more surgeons adapt robotic devices. ISRG's market share is currently only 4%, but Bruce Murray expects the company to grow 50% next year and 20% after that. However, investors have already caught onto this stock and ISRG stock has almost doubled from the March 23 bottom; it has passed its $655 price target and is flirting with $700. Read BDX, BSX, ISRG and Stryker Stock: Top 4 Medical Supply Stocks for our full analysis.

TOP PICK
The leader in robotic surgery. They have only a 3-5% market share, but will grow as doctors grow more comfortable with robotic surgery. The PE is high, but the growth rate will catch up. He sees 50% growth next year and 20% after. This is a high-growth stock. (Analysts’ price target is $655.19)
PAST TOP PICK
(A Top Pick Aug 19/19, Up 15%) They lead in robotic-assisted surgery, though ISRG has only 4% market penetration. They generate tons of cash with lots of recurring revenue. As more surgeries go robotic in the next 20 years, ISRG will lead the way. Buy and put this away for 20 years.
TOP PICK
The maker of surgical robots. They are the leader in the sector and there is no real competition. With only 5% of surgeries being done robotically there is enormous growth ahead. Yield 0% (Analysts’ price target is $546.67)
TOP PICK
The leader in robotic surgery. They sold about 900 units. He thinks they will continue to grow world-wide. (Analysts’ price target is $612.34)
TOP PICK
It is the largest company that you have never heard of. Their business is robots for surgery. It has been under a bit of pressure from a competitor but that competitor only has 4% penetration globally. (Analysts’ price target is $572.35)
COMMENT

Medical robotics? He does not know TMD-T well. He plays the space through and ETF of BOTZ-Q. He prefers ISRG-Q, if you wanted an individual holding.

COMMENT
Own it through an ETF called BOTZ. That is the way he likes to play into the robotics / machine learning space.
TOP PICK

A disruptor in medtech. ISRG builds robotic-assisted surgical devices that are sold to hospitals. Enjoys 85% recurring revenues. Growing steadily for 20 years with good intenational exposure. Their commerical shows a robot sewing the skin on a grape. Stock rose 8% today alone. Again demographics are another tailwind. (Also look at the IHI ETF in the medtech sector.) (Analysts' price target $460.80)

DON'T BUY

Have the robotic methodology for surgical procedures, which has been very successful but it is priced in. Great company. Trading at 35X earnings which is too expensive.

DON'T BUY
Surgical tool for surgeons to use like a robot. He is worried about it getting well ahead of itself. If anything goes wrong there is a lot of air under that stock price.
DON'T BUY
A high-growth story but too expensive for him now. High beta of 1.3.
Showing 46 to 58 of 58 entries